Enorama Pharma AB (ERMA) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.330x

Based on the latest financial reports, Enorama Pharma AB (ERMA) has a cash flow conversion efficiency ratio of 0.330x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-12.09 Million ≈ $-1.30 Million USD) by net assets (Skr-36.63 Million ≈ $-3.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Enorama Pharma AB for the company's overall valuation and market capitalisation.

Enorama Pharma AB - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Enorama Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Enorama Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Enorama Pharma AB ranked by their cash flow conversion efficiency. Explore earnings quality score of Enorama Pharma AB to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Optima Prima Metal Sinergi JK:OPMS	-0.014x
Me Group International PLC LSE:MEGP	0.180x
Wide Open Agriculture Ltd AU:WOA	-0.429x
SKK Holdings Limited NASDAQ:SKK	-0.003x
Gasporox AB (publ) ST:GPX	0.438x
Activex Ltd AU:AIV	-11.887x
APOLLO GROUP-A F:APO	0.090x
Pentanet Ltd AU:5GG	0.068x

Annual Cash Flow Conversion Efficiency for Enorama Pharma AB (2014–2025)

The table below shows the annual cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. View Enorama Pharma AB share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr-23.45 Million ≈ $-2.52 Million	Skr-59.26 Million ≈ $-6.38 Million	2.527x	+155.23%
2024-12-31	Skr7.80 Million ≈ $839.73K	Skr-35.70 Million ≈ $-3.84 Million	-4.575x	-116.20%
2023-12-31	Skr19.54 Million ≈ $2.10 Million	Skr-41.35 Million ≈ $-4.45 Million	-2.116x	-102.43%
2022-12-31	Skr31.52 Million ≈ $3.39 Million	Skr-32.96 Million ≈ $-3.55 Million	-1.045x	+25.99%
2021-12-31	Skr21.35 Million ≈ $2.30 Million	Skr-30.16 Million ≈ $-3.25 Million	-1.413x	+89.09%
2020-12-31	Skr1.78 Million ≈ $191.23K	Skr-23.00 Million ≈ $-2.47 Million	-12.942x	-249.80%
2019-12-31	Skr7.18 Million ≈ $772.64K	Skr-26.56 Million ≈ $-2.86 Million	-3.700x	-371.31%
2018-12-31	Skr17.02 Million ≈ $1.83 Million	Skr-13.36 Million ≈ $-1.44 Million	-0.785x	+13.32%
2017-12-31	Skr7.36 Million ≈ $792.18K	Skr-6.67 Million ≈ $-717.43K	-0.906x	-34.48%
2016-12-31	Skr9.08 Million ≈ $977.10K	Skr-6.11 Million ≈ $-658.02K	-0.673x	-1015.31%
2015-12-31	Skr6.52 Million ≈ $702.09K	Skr480.00K ≈ $51.66K	0.074x	-36.25%
2014-12-31	Skr2.66 Million ≈ $286.26K	Skr307.00K ≈ $33.04K	0.115x	--

About Enorama Pharma AB

ST:ERMA Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$5.54 Million

Skr51.47 Million SEK

Market Cap Rank

#28474 Global

#632 in Sweden

Share Price

Skr0.69

Change (1 day)

-2.54%

52-Week Range

Skr0.26 - Skr3.00

All Time High

Skr170.21